These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31314753)

  • 1. Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach.
    Goss CW; O'Brian K; Dubray C; Fischer PU; Hardy M; Jambulingam P; King CL; Laman M; Lemoine JF; Robinson LJ; Samuela J; Subramanian S; Supali T; Weil GJ; Schechtman KB
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007541. PubMed ID: 31314753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
    Ramaiah KD; Vanamail P; Pani SP; Yuvaraj J; Das PK
    Trop Med Int Health; 2002 Sep; 7(9):767-74. PubMed ID: 12225508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
    Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
    Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of community compliance with spaced, single-dose, mass administrations of diethylcarbamazine or ivermectin, for the elimination of lymphatic filariasis from rural areas of southern India.
    Vanamail P; Ramaiah KD; Subramanian S; Pani SP; Yuvaraj J; Das PK
    Ann Trop Med Parasitol; 2005 Apr; 99(3):237-42. PubMed ID: 15829133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
    Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis.
    Sharma S; Smith ME; Reimer J; O'Brien DB; Brissau JM; Donahue MC; Carter CE; Michael E
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007094. PubMed ID: 31260444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
    Stolk WA; Prada JM; Smith ME; Kontoroupis P; de Vos AS; Touloupou P; Irvine MA; Brown P; Subramanian S; Kloek M; Michael E; Hollingsworth TD; de Vlas SJ
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S260-S266. PubMed ID: 29860286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
    Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India.
    Yuvaraj J; Pani SP; Vanamail P; Ramaiah KD; Das PK
    Trop Med Int Health; 2008 May; 13(5):737-42. PubMed ID: 18346027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets.
    Jones C; Ngasalla B; Derua YA; Tarimo D; Malecela MN
    Int J Infect Dis; 2017 Aug; 61():38-43. PubMed ID: 28527817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of mass drug administration in the program to control imported lymphatic filariasis in Thailand.
    Toothong T; Tipayamongkholgul M; Suwannapong N; Suvannadabba S
    BMC Public Health; 2015 Sep; 15():975. PubMed ID: 26415693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.
    Budge PJ; Herbert C; Andersen BJ; Weil GJ
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006454. PubMed ID: 29768412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.
    Herrick JA; Legrand F; Gounoue R; Nchinda G; Montavon C; Bopda J; Tchana SM; Ondigui BE; Nguluwe K; Fay MP; Makiya M; Metenou S; Nutman TB; Kamgno J; Klion AD
    Clin Infect Dis; 2017 Apr; 64(8):1017-1025. PubMed ID: 28329346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
    Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
    Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis.
    Burgert-Brucker CR; Zoerhoff KL; Headland M; Shoemaker EA; Stelmach R; Karim MJ; Batcho W; Bougouma C; Bougma R; Benjamin Didier B; Georges N; Marfo B; Lemoine JF; Pangaribuan HU; Wijayanti E; Coulibaly YI; Doumbia SS; Rimal P; Salissou AB; Bah Y; Mwingira U; Nshala A; Muheki E; Shott J; Yevstigneyeva V; Ndayishimye E; Baker M; Kraemer J; Brady M
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008301. PubMed ID: 32479495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
    Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
    Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trans R Soc Trop Med Hyg; 2007 Jun; 101(6):555-63. PubMed ID: 17374389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania.
    Fimbo AM; Mlugu EM; Kitabi EN; Kulwa GS; Iwodyah MA; Mnkugwe RH; Kunambi PP; Malishee A; Kamuhabwa AAR; Minzi OM; Aklillu E
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1884-1896. PubMed ID: 37638539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.